Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4 + and CD8 + T cell responses and protection against Leishmania major infection

Journal of Experimental Medicine

Volumn 195, Issue 12, 2002, Pages 1565-1573

  Rhee, Elizabeth G ^a   Mendez, Susana ^b   Shah, Javeed A ^a   Wu, Chang You ^a   Kirman, Joanna R ^a   Turon, Tara N ^a   Davey, Dylan F ^a   Davis, Heather ^c   Klinman, Dennis M ^d   Coler, Rhea N ^e   Sacks, David L ^b   Seder, Robert A ^a  

^a Vaccine Research Center   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Coley Pharmaceutical Group ^*  (Canada)

^d CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^e INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

Author keywords

CD4 + T cells; CD8 + T cells; DNA vaccines; Parasitic infection; Th cells

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; LEISHMANIA VACCINE; OLIGODEOXYNUCLEOTIDE; RECOMBINANT PROTEIN; TRIFUSION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; FEMALE; HELPER CELL; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE DEPLETION; MEMORY CELL; MOUSE; NONHUMAN; PARASITE IMMUNITY; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIGENS, PROTOZOAN; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CPG ISLANDS; FEMALE; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; LEISHMANIA MAJOR; LEISHMANIASIS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; RECOMBINANT PROTEINS;

EID: 0037124332     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20020147     Document Type: Article

References (36)

1. Recombinant interleukin 12 cures mice infected with Leishmania major
2. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response
3. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis
4. Resistance to Leishmania major induced by tolerance to a single antigen
5. + T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice
6. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon-γ-independent mechanism
7. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
8. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major
9. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
10. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge
11. The potency and durability of DNA-and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge
12. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity
13. + T cells
14. Contribution of CpG motifs to the immunogenicity of DNA vaccines
15. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
16. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
17. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants
18. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ
19. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
20. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins
21. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs
22. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity
23. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism
24. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
25. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-γ-dependent mechanisms
26. CpG-DNA-mediated transient lymphadenopathy is associated with a state of Th1 predisposition to antigen-driven responses
27. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal nmrine leishmaniasis
28. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis
29. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family
30. Immunization with a poly-protein vaccine consisting of the T cell antigens TSA, LmSTI1 and LeIF protects against leishmaniasis
31. + T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major
32. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease
33. Immunogenicity and safety of autoclaved Leishmania major plus BCG vaccine in healthy Sudanese volunteers
34. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan
35. A Toll-like receptor recognizes bacterial DNA
36. CpG oligodeoxynucleotides as vaccine adjvuants in primates